Cyxone presents at BioStock Live 9 March 2021
CEO Tara Heitner will present the latest updates in Cyxone on 9 March at the online event BioStock Live.Contact Tara Heitner, CEOTel: +46 70 781 88 08Email: tara.heitner@cyxone.comAdelgatan 21211 22 Malmö, Sweden About Cyxone Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19